Target Name: MTX1
NCBI ID: G4580
Review Report on MTX1 Target / Biomarker Content of Review Report on MTX1 Target / Biomarker
MTX1
Other Name(s): MTX1_HUMAN | MTX | Mitochondrial outer membrane import complex protein 1 | MTX1 variant 1 | mitochondrial outer membrane import complex protein 1 | MTXN | Metaxin 1, transcript variant 1 | Metaxin-1 | metaxin 1

MTX1: A Protein Targeted for Therapeutic Use

MTX1 (MTX1_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, kidneys, and liver. It is a member of the superfamily of G protein-coupled receptors (GPCRs), which are a family of transmembrane proteins that play an important role in cellular signaling.

MTX1 is highly conserved between various species, and its primary function is not well understood. However, it is known to be involved in a variety of physiological processes, including cell survival, growth, and angiogenesis.

One of the most promising aspects of MTX1 is its potential as a drug target. due to its conserved nature and various functions, researchers have identified several potential drug-like compounds that can interact with MTX1. These compounds can modulate the activity of MTX1 and its downstream signaling pathways, leading to therapeutic effects.

One of the first drugs to be developed as a potential MTX1 inhibitor was a small molecule called T0720. T0720 is a potent inhibitor of MTX1, with a binding constant of 1 nM. T0720 has been shown to block the effects of several neurotransmitters, including neurotrophic factors and ionotropic neurotransmitters, on MTX1-mediated signaling pathways.

Another drug that is being investigated as an MTX1 inhibitor is a peptide called P200. P200 is a 20-amino acid peptide that contains a unique disulfide bond. P200 has been shown to be a potent inhibitor of MTX1, with a binding constant of 10 nM. P200 also has been shown to block the effects of several neurotransmitters, including neurotrophic factors and ionotropic neurotransmitters, on MTX1-mediated signaling pathways.

Another approach to target MTX1 is through the use of RNA interference (RNAi) technology. RNAi is a technique that involves the introduction of small interfering RNA (siRNA) into cells to suppress the expression of specific genes. MTX1 is a target gene that has been shown to be involved in several diseases, including neurodegenerative diseases, cancer, and cardiovascular diseases. By using RNAi to knock down the expression of MTX1, researchers have been able to generate MTX1-deficient animals and test their potential therapeutic effects.

In addition to these therapeutic approaches, researchers are also exploring the use of MTX1 as a biomarker for certain diseases. MTX1 is highly expressed in several tissues of the human body, including the brain, heart, and liver, and its levels can be affected by a variety of factors, including neurodegenerative diseases, cancer, and cardiovascular diseases. By using techniques such as Western blotting, researchers have been able to detect changes in MTX1 levels in response to these diseases, providing a potential source of diagnostic information.

Overall, MTX1 is a protein that is involved in a variety of physiological processes and is a potential drug target for several diseases. While more research is needed to fully understand its functions and potential therapeutic uses, the development of compounds and techniques such as RNAi and Western blotting provide promising avenues for future research.

Protein Name: Metaxin 1

Functions: Involved in transport of proteins into the mitochondrion. Essential for embryonic development (By similarity)

The "MTX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MTX2 | MTX3 | mu-Calpain (calpain 1) | MUC1 | MUC12 | MUC13 | MUC15 | MUC16 | MUC17 | MUC19 | MUC2 | MUC20 | MUC20P1 | MUC21 | MUC22 | MUC3A | MUC3B | MUC4 | MUC5AC | MUC5B | MUC6 | MUC7 | MUC8 | Mucin | MUCL1 | MUCL3 | MUL1 | Multisubunit histone acetyltransferase complex | MUPP | MUS81 | Muscarinic Acetylcholine Receptor (mAChR) | MUSK | MUSTN1 | MUTYH | MVB12A | MVB12B | MVD | MVK | MVP | MX1 | MX2 | MXD1 | MXD3 | MXD4 | MXI1 | MXRA5 | MXRA5Y | MXRA7 | MXRA8 | MYADM | MYADML | MYADML2 | MYB | MYBBP1A | MYBL1 | MYBL2 | MYBPC1 | MYBPC2 | MYBPC3 | MYBPH | MYBPHL | MYC | MYCBP | MYCBP2 | MYCBP2-AS1 | MYCBPAP | MYCL | MYCL-AS1 | MYCLP1 | MYCN | MYCNOS | MYCNUT | MYCT1 | MYD88 | MYDGF | MYEF2 | Myelin Protein | MYEOV | MYF5 | MYF6 | MYG1 | MYH1 | MYH10 | MYH11 | MYH13 | MYH14 | MYH15 | MYH16 | MYH2 | MYH3 | MYH4 | MYH6 | MYH7 | MYH7B | MYH8 | MYH9 | MYHAS | MYL1 | MYL10 | MYL11